Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting Jun 8, 2022 08:00AM
Ocuphire (OCUP) PT Raised to $22 at Cantor Fitzgerald, Following Clinical Business Update Jun 30, 2021 11:08AM
Ocuphire (OCUP) PT Raised to $20 at Cantor Fitzgerald Mar 15, 2021 12:00PM
Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021 Feb 11, 2021 09:12AM
Ocuphire to be Featured in Cantor Fitzgerald Fireside Chat with Equity Research Analyst Kristen Kluska Dec 8, 2020 07:00AM


Nov 5, 2020 08:33PM Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP